CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study Thomas O. Bergmeijer, MD, Paul W.A. Janssen, MD, Jurjan C. Schipper, MD, Khalid Qaderdan, MD, Maycel Ishak, MD, Rianne S. Ruitenbeek, BSc, Folkert W. Asselbergs, MD, PhD, FESC, Arnoud W.J. van ‘t Hof, MD, PhD, Willem J.M. Dewilde, MD, Fabrizio Spanó, MD, Jean-Paul R. Herrman, MD, PhD, Johannes C. Kelder, MD, PhD, Maarten J. Postma, PharmD, PhD, Anthonius de Boer, MD, PhD, Vera H.M. Deneer, PharmD, PhD, Jurriën M. ten Berg, MD, PhD, FESC, FACC American Heart Journal Volume 168, Issue 1, Pages 16-22.e1 (July 2014) DOI: 10.1016/j.ahj.2014.03.006 Copyright © 2014 Mosby, Inc. Terms and Conditions
Figure Flowchart. American Heart Journal 2014 168, 16-22.e1DOI: (10.1016/j.ahj.2014.03.006) Copyright © 2014 Mosby, Inc. Terms and Conditions